文献速递头颈神经MR

鼻咽癌免疫治疗反应预测:基于MRI影像组学特征与程序性死亡配体1表达评分的比较研究

Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score.
PubMed 文献 · Eur Radiol · 2025-01-24

影像组学评分在训练集(AUC 0.790 vs. 0.645,p=0.025)和验证集(AUC 0.735 vs. 0.608,p=0.038)均显著高于CPS,多因素分析显示影像组学评分为独立影响因素(OR=19.963,p<0.001)。

要点

  • 治疗前MRI影像组学评分预测鼻咽癌免疫治疗客观缓解的AUC在训练集为0.790、验证集为0.735,均高于PD-L1 CPS。
  • 影像组学评分≥0.5的患者无进展生存期长于评分<0.5者(log-rank p<0.01)。
  • 影像组学评分是预测免疫治疗反应的独立影响因素(OR=19.963,p<0.001)。

核心结论

  • 基于MRI的影像组学特征在预测鼻咽癌患者免疫治疗反应方面优于PD-L1表达评分。

研究设计与样本

  • 比较研究,纳入2019年1月至2022年6月接受免疫治疗的连续鼻咽癌患者,分为训练集111例和验证集66例;从治疗前MR图像提取肿瘤影像组学特征,采用LASSO算法筛选特征并构建影像组学评分,以免疫组化计算的PD-L1联合阳性评分(CPS)作为对照,用ROC曲线评估预测性能。

诊断标准与关键数值

  • LASSO算法筛选出11个区分能力最强的影像组学特征构建评分;预测免疫治疗客观缓解的AUC:训练集影像组学评分0.790 vs. CPS 0.645(p=0.025),验证集影像组学评分0.735 vs. CPS 0.608(p=0.038)。

临床应用与阅片要点

  • 作者认为基于MRI的影像组学是有前景的无创工具,可用于预测鼻咽癌免疫治疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare an MRI-based radiomics signature with the programmed cell death ligand 1 (PD-L1) expression score for predicting immunotherapy response in nasopharyngeal carcinoma (NPC).

METHODS: Consecutive patients with NPC who received immunotherapy between January 2019 and June 2022 were divided into training (n = 111) and validation (n = 66) sets. Tumor radiomics features were extracted from pretreatment MR images. PD-L1 combined positive score (CPS) was calculated using immunohistochemistry. The least absolute shrinkage and selection operator (LASSO) algorithm was used for feature selection and radiomics signature construction. Receiver operating characteristic (ROC) curve analysis was performed to assess prediction performance.

RESULTS: A total of eleven radiomics features with the greatest discrimination capability were identified by the LASSO algorithm to construct the radiomics signature. In predicting patients with objective response to immunotherapy, radiomics score (Rd-score) yielded a significantly higher area under the ROC curve than that of CPS in both the training (0.790 vs. 0.645, p = 0.025) and the validation (0.735 vs. 0.608, p = 0.038) sets. Multivariate analysis identified the Rd-score as an independent influencing factor in predicting immunotherapy response (odds ratio = 19.963, p < 0.001). Kaplan-Meier analysis indicated that patients with Rd-score ≥ 0.5 showed longer progression-free survival than patients with Rd-score < 0.5 (log-rank p < 0.01).

CONCLUSION: An MRI-based radiomics signature demonstrated greater efficacy than the PD-L1 expression score in predicting immunotherapy response in patients with NPC.

KEY POINTS: Question How does an MRI-based radiomics signature compare with the programmed cell death ligand 1 expression score for predicting immunotherapy response in nasopharyngeal carcinoma? Findings The MRI-based radiomics signature demonstrated superior predictive value compared with programmed cell death ligand 1 expression score in identifying immunotherapy responders. Clinical relevance MRI-based radiomics are a promising novel noninvasive tool for predicting immunotherapy outcomes in nasopharyngeal carcinoma.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Mai H, Li L, Xin X, et al. Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score. Eur Radiol. 2025. PMID: 39853331. doi:10.1007/s00330-025-11350-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。